Takeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Down 17.4% in October

by · The Cerbat Gem

Takeda Pharmaceutical Company Limited (NYSE:TAK – Get Free Report) saw a significant decrease in short interest in October. As of October 31st, there was short interest totalling 6,030,000 shares, a decrease of 17.4% from the October 15th total of 7,300,000 shares. Based on an average trading volume of 1,650,000 shares, the days-to-cover ratio is presently 3.7 days.

Institutional Trading of Takeda Pharmaceutical

Hedge funds have recently made changes to their positions in the business. Envestnet Portfolio Solutions Inc. raised its holdings in Takeda Pharmaceutical by 7.4% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 25,763 shares of the company’s stock valued at $358,000 after acquiring an additional 1,778 shares during the period. Van ECK Associates Corp boosted its stake in Takeda Pharmaceutical by 21.1% in the 2nd quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock valued at $26,408,000 after purchasing an additional 356,069 shares during the period. Blair William & Co. IL grew its holdings in Takeda Pharmaceutical by 6.5% in the 1st quarter. Blair William & Co. IL now owns 12,649 shares of the company’s stock valued at $176,000 after buying an additional 777 shares in the last quarter. O Shaughnessy Asset Management LLC increased its position in Takeda Pharmaceutical by 43.2% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 88,663 shares of the company’s stock worth $1,232,000 after buying an additional 26,735 shares during the period. Finally, Creative Planning lifted its holdings in shares of Takeda Pharmaceutical by 46.3% during the third quarter. Creative Planning now owns 157,630 shares of the company’s stock worth $2,242,000 after buying an additional 49,871 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Up 0.4 %

TAK traded up $0.05 during trading on Friday, reaching $13.62. The company had a trading volume of 2,196,974 shares, compared to its average volume of 1,827,111. The business’s fifty day moving average price is $14.27 and its 200 day moving average price is $13.82. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77. Takeda Pharmaceutical has a 12 month low of $12.57 and a 12 month high of $15.08. The company has a market cap of $43.34 billion, a P/E ratio of 23.33, a PEG ratio of 0.26 and a beta of 0.54.

Takeda Pharmaceutical Company Profile

(Get Free Report)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Featured Stories